Journal rankings · indicator year 2009
Choose a field to open its ranking, or a journal to find its row in its subfield’s list.
Field ranking · 2009
Pharmacology, Toxicology and Pharmaceutics journal rankings 2009
43 ranked journals · Field in Life Sciences
Pharmacology, Toxicology and Pharmaceutics has 43 ranked journals in 2009. The median journal has an OJR of 0.97, below the world average of 1.00, up 0.02 on 2008; Q1 starts at OJR 1.63. The top three are Current Drug Metabolism, Critical Reviews in Therapeutic Drug Carrier Systems, and Pharmacogenetics and Genomics.
Ranks and citation indicators: 2009. Journal access status and listed APC: source snapshot September 23, 2026.
Journals whose main subfield sits in this category and that published at least 30 citable documents (articles, reviews and conference papers) in 2006–2008, the window the 2009 score is computed on.
The OpenJournalRank Indicator (OJR) is a free, publicly available metric of a journal’s field-normalized citation impact, computed from open OpenAlex citation data. It compares citations to a journal’s papers from the previous three years with the world average for papers of the same subfield, year and type, so 1.00 is the world average and values can be compared across fields. It is computed with the NCI3 method.
The middle OJR among ranked journals in this category: half score higher, half lower. 1.00 is the world average for papers of the same subfield, year and type.
The dot is this category, the solid tick is the median of all ranked journals and the dashed line is the world average.
Share of ranked journals in this category that are fully open access, so every paper is free to read. Hybrid journals, which sell subscriptions and open single papers for a fee, are not counted.
Median list price of the article processing charge, in US dollars, among ranked journals in this category that list a price above zero. Journals with a listed APC of $0 and journals with no known price are left out of this median. The At a glance table below gives a second median that includes the $0 prices.
Subfields in Pharmacology, Toxicology and Pharmaceutics (4)
Up to Life Sciences43 ranked journals
Filters
Rank is the position by OJR within the list on screen; 1 is the highest. | OJR is field-normalized 3-year citation impact: 1.00 is the world average for papers of the same subfield, year and type, so values compare across fields. The badge is the journal’s quartile in this list. | Citations per paper over a two-year window, counted from OpenAlex. It is not field-normalized, so compare it only between journals of the same field. ▲ or ▼ is the change from 2008. This is OpenJournalRank’s own count, not Clarivate’s Journal Impact Factor. | Citable documents (articles, reviews and conference papers) published in 2006–2008, the window the 2009 OJR is computed on. A journal needs at least 30 to be ranked. | Share of the journal’s 2006–2008 papers that are free to read in any open-access form. The green OA tag next to a title marks a fully open-access journal. | List price of the article processing charge in US dollars. “$0 listed” means the listed price is zero; a dash means no price is listed. | The line is the journal’s OJR from 2000 to 2009. | Compare |
|---|---|---|---|---|---|---|---|
1Current Drug MetabolismBentham Science Publishers · Netherlands | 2.88Q1 | 4.95 0.20 up from 2008 | 241 | 9% | — | ||
2Critical Reviews in Therapeutic Drug Carrier SystemsBegell House · United States | 2.46Q1 | 4.42 0.58 up from 2008 | 39 | 6% | — | ||
3Pharmacogenetics and GenomicsLippincott Williams & Wilkins · United Kingdom | 2.34Q1 | 4.94 0.31 down from 2008 | 342 | 41% | — | ||
4The Pharmacogenomics JournalSpringer Nature · United Kingdom | 2.31Q1 | 4.82 1.02 down from 2008 | 153 | 21% | $4,890 | ||
5Pharmaceutical ResearchSpringer Science+Business Media · United States | 2.15Q1 | 4.51 0.44 up from 2008 | 887 | 27% | $4,690 | ||
6Drug Metabolism and DispositionAmerican Society for Pharmacology and Experimental Therapeutics · United States | 2.13Q1 | 4.14 0.15 up from 2008 | 929 | 25% | $3,500 | ||
7Expert Opinion on Drug Metabolism & ToxicologyTaylor & Francis · United Kingdom | 2.02Q1 | 3.79 0.27 up from 2008 | 284 | 9% | — | ||
8Expert Opinion on Drug DeliveryTaylor & Francis · United Kingdom | 1.97Q1 | 4.07 0.24 up from 2008 | 198 | 8% | — | ||
9European Journal of Pharmaceutics and BiopharmaceuticsElsevier BV · Netherlands | 1.90Q1 | 3.17 0.29 up from 2008 | 776 | 5% | $4,210 | ||
10XenobioticaTaylor & Francis · United Kingdom | 1.78Q1 | 3.85 1.81 up from 2008 | 257 | 8% | — | ||
11International Journal of PharmaceuticsElsevier BV · Netherlands | 1.63Q1 | 3.08 0.26 up from 2008 | 1,885 | 8% | $4,650 | ||
12PharmacogenomicsFuture Medicine · United Kingdom | 1.60Q2 | 3.63 0.13 down from 2008 | 472 | 23% | — | ||
13Journal of Analytical ToxicologyOxford University Press · United Kingdom | 1.59Q2 | 3.10 1.06 up from 2008 | 329 | 33% | $4,823 | ||
14Drug Metabolism and PharmacokineticsElsevier BV · Japan | 1.54Q2 | 2.87 0.19 down from 2008 | 181 | 4% | $3,580 | ||
15Current Drug DeliveryBentham Science Publishers · Netherlands | 1.53Q2 | 2.76 0.42 down from 2008 | 113 | 3% | — | ||
16Expert Opinion on Drug SafetyTaylor & Francis · United Kingdom | 1.50Q2 | 3.03 0.13 up from 2008 | 219 | 5% | — | ||
17European Journal of Pharmaceutical SciencesOAElsevier BV · Netherlands | 1.46Q2 | 2.09 0.66 down from 2008 | 530 | 6% | $3,070 | ||
18Drug SafetyAdis, Springer Healthcare · New Zealand | 1.18Q2 | 2.15 0.06 up from 2008 | 674 | 3% | $4,990 | ||
19Drug metabolism and drug interactionsDe Gruyter · Germany | 1.16Q2 | 2.29 1.47 up from 2008 | 41 | 0% | — | ||
20AAPS PharmSciTechSpringer Science+Business Media · United States | 1.08Q2 | 1.68 0.03 down from 2008 | 386 | 100% | $4,190 | ||
21Journal of MicroencapsulationTaylor & Francis · United Kingdom | 0.98Q2 | 1.40 0.24 down from 2008 | 263 | 5% | — | ||
22Drug DeliveryOATaylor & Francis · United Kingdom | 0.97Q2 | 1.64 0.20 up from 2008 | 186 | 94% | $2,864 | ||
23Journal of Fluorine ChemistryElsevier BV · Netherlands | 0.93Q3 | 1.63 0.01 up from 2008 | 660 | 6% | $3,660 | ||
24Recent Patents on Drug Delivery & FormulationBentham Science Publishers · Netherlands | 0.89Q3 | 1.53 0.72 up from 2008 | 51 | 3% | — | ||
25Assay and Drug Development TechnologiesMary Ann Liebert, Inc. · United States | 0.79Q3 | 2.03 0.32 up from 2008 | 216 | 29% | — | ||
26Biopharmaceutics & Drug DispositionWiley · United Kingdom | 0.78Q3 | 1.51 0.10 down from 2008 | 150 | 23% | $3,800 | ||
27Journal of Pharmaceutical InnovationSpringer Science+Business Media · United Kingdom | 0.78Q3 | 0.88 0.12 down from 2008 | 50 | 25% | $3,990 | ||
28Pharmaceutical Development and TechnologyTaylor & Francis · United States | 0.69Q3 | 1.09 0.14 down from 2008 | 190 | 3% | — | ||
29Clinical and Translational ScienceOAWiley · United Kingdom | 0.67Q3 | 1.33no 2008 value | 58 | 61% | $3,630 | — | |
30Drug Development and Industrial PharmacyTaylor & Francis · United States | 0.61Q3 | 1.09 0.15 down from 2008 | 501 | 1% | — | ||
31Current Chemical BiologyBentham Science Publishers · Netherlands | 0.53Q3 | 1.16 0.05 up from 2008 | 104 | 10% | — | ||
32Forensic ToxicologySpringer Science+Business Media · Japan | 0.50Q3 | 1.21 0.55 up from 2008 | 58 | 12% | $2,990 | ||
33Drug Metabolism LettersBentham Science Publishers · Netherlands | 0.43Q3 | 0.78 0.26 up from 2008 | 99 | 5% | — | ||
34Current Drug TherapyBentham Science Publishers · Netherlands | 0.37Q4 | 0.73 0.02 up from 2008 | 79 | 7% | — | ||
35Recent Patents on NanotechnologyBentham Science Publishers · Netherlands | 0.37Q4 | 0.61 0.39 down from 2008 | 59 | 7% | — | ||
36Dissolution TechnologiesUnited States | 0.36Q4 | 0.49 0.32 down from 2008 | 68 | 88% | — | ||
37YAKUGAKU ZASSHIOAPharmaceutical Society of Japan · Japan | 0.35Q4 | 0.67 0.01 up from 2008 | 658 | 97% | — | ||
38Journal of Drug Delivery Science and TechnologyElsevier BV · France | 0.32Q4 | 0.60 0.01 up from 2008 | 196 | 4% | $3,810 | ||
39European Journal of Drug Metabolism and PharmacokineticsAdis, Springer Healthcare · France | 0.29Q4 | 0.63 0.11 up from 2008 | 111 | 0% | $2,690 | ||
40Scientia PharmaceuticaOAÖsterreichische Apotheker-Verlagsgesellschaft m. b. H. · Switzerland | 0.23Q4 | 0.41 0.24 up from 2008 | 83 | 100% | $1,207 | ||
41Annales de Toxicologie AnalytiqueElsevier BV · France | 0.16Q4 | 0.33 0.13 up from 2008 | 91 | 88% | $3,140 | ||
42Journal of Pharmaceutical Marketing & ManagementHaworth Press · United States | 0.12Q4 | 0.00 0.03 down from 2008 | 45 | — | — | ||
| 0.02Q4 | 0.02 0.02 up from 2008 | 81 | 100% | — |
Subfields of Pharmacology, Toxicology and Pharmaceutics, compared.
Journals
Citations made in 2009. Corpus-wide, 71.4% of core-journal articles and reviews published that year have at least one matched reference; the share varies by journal and field.
14 additional Pharmacology, Toxicology and Pharmaceutics journals with metrics are unranked under this release’s eligibility rules: a journal needs at least 30 citable documents in 2006–2008, at least 80% of them with a subfield, and a positive world-average expectation. Ranks are within the whole category; filters hide rows without re-ranking. OJR excludes self-citations.
At a glance
Indicator year: 2009. Publication window: 2006–2008. How these summaries are calculated
- Ranked journals
- 43
- Window papers (baseline)
- 41,640 +31.7% from indicator year 2006
- Median OJR
- 0.97 +7.2% from indicator year 2006
- Rising journals (2025)
- 4Comparison-group list (4)
Window papers are the baseline paper population: citable papers (articles, reviews and conference papers) from 2006–2008 in all journals of the world-average baseline, including non-core journals, counted by each paper’s own subfield. They are not the papers of the ranked journals alone.
| Measure | Year series | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ranked journals | 23 | 27 | 30 | 32 | 32 | 34 | 37 | 38 | 40 | 43 | 44 | 49 | 54 | 61 | 69 | 71 | 74 | 71 | 73 | 75 | 70 | 72 | 75 | 73 | 72 | 68 | |
| Window papers (baseline) | 20,428 | 21,714 | 23,158 | 25,397 | 26,889 | 29,157 | 31,606 | 34,777 | 38,146 | 41,640 | 45,814 | 49,553 | 53,613 | 56,245 | 59,173 | 59,681 | 59,061 | 56,321 | 53,536 | 51,719 | 51,606 | 54,267 | 56,608 | 57,539 | 56,944 | 58,541 | |
| Median OJR | 0.620 | 0.717 | 0.722 | 0.88 | 0.86 | 0.83 | 0.91 | 1.11 | 0.9471 | 0.97 | 0.949 | 1.03 | 0.9469 | 0.80 | 0.70 | 0.720 | 0.61 | 0.7184 | 0.74 | 0.628 | 0.77 | 0.621 | 0.67 | 0.630 | 0.625 | 0.7176 |
| Measure | Category statistic | Eligible population |
|---|---|---|
| Journal self-citation share | Median: 2.7% | 62 journals |
| Retracted papers per 1,000 | Pooled rate: 1.221 per 1,000 | 51 journals |
| Output growth | Median: -1.6% | 60 journals |
| Open access share | Median: 44.5% | 68 journals |
| Listed APC (USD) | Median including $0 listed prices: $3,605 | 32 ranked journals with a known listed price, including $0 listed prices |
| International collaboration share | Median: 22.2% | 67 journals |
| Review share | Median: 0.4% | 68 journals |
| Articles-only OJR | Median: 0.74 | 68 journals |
| Uncited share | Median: 25.2% | 68 journals |
| Citation concentration | Median: 43.7% | 68 journals |
How to read these rankings
- OJR, the OpenJournalRank Indicator
- A field-normalized 3-year citation impact, computed from OpenAlex with the NCI3 method. It divides the citations a journal’s papers received by the world average for papers of the same subfield, year and type, so 1.00 is the world average and 2.00 means twice as many citations as expected. Because it is normalized, it can be compared across fields. Read the methodology
- Quartiles
- Q1 to Q4 split the ranked journals of the list you are viewing into four equal groups by OJR. A journal’s quartile depends on the list: the same journal can be Q1 in its subfield and Q2 among all journals.
- Impact factor (2-year)
- Citations per paper over a two-year window, counted from OpenAlex. It is easy to compare with familiar impact factors but is not field-normalized, so compare it only within a field. It is not Clarivate’s Journal Impact Factor. Why it differs from the Journal Impact Factor
- Rank ranges
- Each rank in the latest year carries a likely range from 1,000 resamples of the journal’s papers. Where two journals’ ranges overlap, the data cannot tell them apart, so treat neighbouring ranks as ties.